FDA inspection
Cima Labs, Inc.: FDA inspection ending Aug 1, 2003
FDA inspection 288898 · Voluntary Action Indicated (VAI) · Eden Prairie, MN
Key facts
| Inspection ID | 288898 |
|---|---|
| Firm | Cima Labs, Inc. |
| FEI number | 1000520140 |
| Address | 10000 Valley View Rd |
| City | Eden Prairie |
| State | MN |
| ZIP | 55344-3510 |
| Fiscal year | 2003 |
| Inspection end date | Aug 1, 2003 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data